Department of Ophthalmology, Training and Research Hospital, Bolu Abant Izzet Baysal University, Bolu, Turkey.
Department of Biochemistry, Polatlı Duatepe State Hospital, Ankara, Turkey.
Eye (Lond). 2021 Nov;35(11):3123-3130. doi: 10.1038/s41433-020-01347-3. Epub 2021 Jan 19.
To determine whether subconjunctival or intrastromal administration of anti-VEGF agents is more effective on suture-induced corneal neovascularization (CoNV) in rabbits.
CoNV was induced in 48 eyes of 24 New Zealand white rabbits by using an 8/0 silk suture. On the 7th day after suturing, the rabbits were divided into four treatment groups as follows: six rabbits received subconjunctival bevacizumab (group 1), six rabbits received subconjunctival aflibercept (group 2), six rabbits received intrastromal bevacizumab (group 3) and six rabbits received intrastromal aflibercept (group 4). On the 7th and 14th days after suturing, the CoNV area was calculated by standardised analysis of photographs using the Image-J program. On the 14th day after suturing, all rabbits were sacrificed and then corneal tissue was harvested for the analysis of vascular endothelial growth factor (VEGF)-A, VEGF-B and placental growth factor (PIGF) levels.
On the 7th day after suturing, CoNV areas were 17.10 ± 2.98, 18.88 ± 3.78, 17.36 ± 4.52, 18.57 ± 4.16 and 17.31 ± 2.81 mm in the groups 1-4 and control group, respectively. On the 7th day after intervention and removal of suture, CoNV areas were 4.85 ± 1.99, 6.66 ± 1.73, 2.83 ± 1.08, 2.63 ± 1.16 and 11.93 ± 2.64 mm in the group 1-4 and control group, respectively. CoNV area was reduced by 88.1% and 82.5% in eyes receiving intrastromal aflibercept and bevacizumab, respectively (both p < 0.001), and by 64.5% and 69.9% in eyes receiving subconjunctival aflibercept and bevacizumab, respectively (both p = 0.001).
Intrastromal anti-VEGF therapy regressed CoNV more effectively than subconjunctival therapy regardless of the type of anti-VEGF agent.
比较玻璃体内和基质内给予抗血管内皮生长因子（VEGF）药物对兔缝线诱导性角膜新生血管（CoNV）的疗效。
用 8/0 丝线缝合 24 只新西兰白兔的 48 只眼，于第 7 天诱导 CoNV。缝线后第 7 天，将兔子分为 4 个治疗组：6 只兔子接受玻璃体内贝伐单抗（第 1 组），6 只兔子接受玻璃体内阿柏西普（第 2 组），6 只兔子接受基质内贝伐单抗（第 3 组），6 只兔子接受基质内阿柏西普（第 4 组）。缝线后第 7 天和第 14 天，用 Image-J 程序对照片进行标准化分析计算 CoNV 面积。缝线后第 14 天处死所有兔子，取角膜组织分析血管内皮生长因子（VEGF）-A、VEGF-B 和胎盘生长因子（PIGF）水平。
缝线后第 7 天，第 1-4 组和对照组 CoNV 面积分别为 17.10±2.98、18.88±3.78、17.36±4.52、18.57±4.16 和 17.31±2.81mm。缝线去除后第 7 天，第 1-4 组和对照组 CoNV 面积分别为 4.85±1.99、6.66±1.73、2.83±1.08、2.63±1.16 和 11.93±2.64mm。基质内阿柏西普和贝伐单抗组 CoNV 面积分别减少 88.1%和 82.5%（均 p<0.001），玻璃体内阿柏西普和贝伐单抗组 CoNV 面积分别减少 64.5%和 69.9%（均 p=0.001）。
无论使用何种抗 VEGF 药物，基质内抗 VEGF 治疗消退 CoNV 的效果均优于玻璃体内治疗。
